Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7071-7080 Newer>

The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool January 13, 2011 Seth Jayson	Does Novo Nordisk Measure Up? With recent TTM margins all exceeding historical averages, Novo Nordisk looks like it's doing fine.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool January 11, 2011 Brian Orelli	A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme.
The Motley Fool January 11, 2011 Brian Orelli	An Undeserved Kick in the Pants Celgene gets knocked around.
The Motley Fool January 11, 2011 Seth Jayson	Here's How Endo Pharmaceuticals Is Making You So Much Cash With questionable cash flows actually reducing operating cash flow slightly, Endo Pharmaceuticals' cash flows look clean.
The Motley Fool January 11, 2011 Seth Jayson	Does This Make Biogen Idec a Sell? For the last fully reported fiscal quarter, Biogen Idec's year-over-year revenue grew 4.9%, and its AR grew 12.6%. That looks OK.
The Motley Fool January 10, 2011 Brian Orelli	By the Way, We Need to Run Another Trial InterMune has decided to run a new trial to gain U.S. approval on its idiopathic pulmonary fibrosis drug.
The Motley Fool January 10, 2011 Travis Hoium	Auxilium Pharmaceuticals Shares Popped: What You Need to Know Auxilium Pharmaceuticals shares are 15% higher today after the company released preliminary fourth-quarter results.
The Motley Fool January 10, 2011 Seth Jayson	Does This Make Mindray Medical International a Sell? For the last fully reported fiscal quarter, Mindray Medical International's year-over-year revenue grew 11.3%, and its AR grew 22.2%. That's a yellow flag.
<Older 7071-7080 Newer> Return to current articles.